Neurogene (NGNE) Debt to Equity (2013)
Neurogene posted quarterly Debt to Equity of -$0.03 for Q4 2013.
Neurogene (NGNE) has 1 years of Debt to Equity data on file, last reported at -$0.03 in Q4 2013.
- For the quarter ending Q4 2013, Debt to Equity changed N/A year-over-year to -$0.03; the trailing twelve-month figure through Dec 2013 stood at -$0.03 (changed N/A YoY), and the FY2013 full-year result was -$0.03, changed N/A from the prior year.
- Debt to Equity for Q4 2013 stood at -$0.03.
- Across five years, Debt to Equity topped out at -$0.03 in Q4 2013 and bottomed at -$0.03 in Q4 2013.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 0.06 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Neurogene | 632.14 Mn | 632.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | -0.03 |